Intermountain Medical Center

Public research footprint of Intermountain Medical Center, compiled from the ClinicalTrials.gov public registry.

595

Registered studies

197

Active

Recruiting now

291

Completed

Stopped or withdrawn

Most-studied conditions

Acute Respiratory Distress Syndrome (ARDS) · Recurrent Melanoma · Metastatic Non-Cutaneous Melanoma · EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Recently updated registry entries

NCT02196181 — Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer… (Active Not Recruiting)
NCT02506153 — Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or… (Active Not Recruiting)
NCT02224781 — Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… (Active Not Recruiting)

Work at Intermountain Medical Center?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.